ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Akkerman OW, de Lange WC, Schölvinck EH, Wolters B, Aartsma Y, van der Werf TS, van Hest R, 2016. Implementing tuberculosis entry screening for asylum seekers: the Groningen experience. Eur Respir J 48: 261–264.
-
2.
Heudorf U, Albert-Braun S, Hunfeld KP, Birne FU, Schulze J, Strobel K, Petscheleit K, Kempf VA, Brandt C, 2016. Multidrug-resistant organisms in refugees: prevalences and impact on infection control in hospitals. GMS Hyg Infect Control 11: Doc16.
-
3.
Alsaad N, van Altena R, Pranger AD, van Soolingen D, de Lange WC, van der Werf TS, Kosterink JG, Alffenaar JW, 2013. Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis. Eur Respir J 42: 504–512.
-
4.
Werkgroep Infectie Preventie, 2012. Meticilline-Resistente Staphylococcus aureus (MRSA). Available at: http://www.rivm.nl/dsresource?objectid=3f054354-ff4a-43ef-91f9-7c6f0417be95&type=org&disposition=inline. Accessed May 22, 2017.
-
5.
Mascini E, Hendrix R, Vos G, Cohen Stuart J, 2015. Correctie in Alinea Over Meldingsplichtig–Alertheid Gevraagd Voor Mogelijk Risico van MRSA/BRMO-Dragerschap Onder Asielzoekers. Available at: http://www.rivm.nl/dsresource?objectid=06625bb2-ab97-440c-8087-f03c9b540d17&type=org&disposition=inline. Accessed May 22, 2017.
-
6.
Hargreaves S, Lönnroth K, Nellums LB, Olaru ID, Nathavitharana RR, Norredam M, Friedland JS, 2017. Multidrug-resistant tuberculosis and migration to Europe. Clin Microbiol Infect 23: 141–146.
-
7.
Reinheimer C, Kempf VA, Göttig S, Hogardt M, Wichelhaus TA, O’Rourke F, Brandt C, 2016. Multidrug-resistant organisms detected in refugee patients admitted to a University Hospital, Germany June–December 2015. Euro Surveill 21: 30110.
-
8.
Heudorf U, Krackhardt B, Karathana M, Kleinkauf N, Zinn C, 2016. Multidrug-resistant bacteria in unaccompanied refugee minors arriving in Frankfurt am Main, Germany, October to November 2015. Euro Surveill 21: 30109.
-
9.
van Altena R et al. 2016. Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly. Eur Respir J 48: 1800–1802.
-
10.
Van Altena R, de Vries G, Haar CH, de Lange WC, Magis-Escurra C, van den Hof S, van Soolingen D, Boeree MJ, van der Werf TS, 2015. Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000–2009. Int J Tuberc Lung Dis 19: 406–412.
-
11.
Padmini N, Ajilda AAK, Sivakumar N, Selvakumar G, 2017. Extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae: critical tools for antibiotic resistance pattern. J Basic Microbiol 57: 460–470.
-
12.
Gröschel MI, Omansen TF, de Lange W, van der Werf TS, Lokate M, Bathoorn E, Akkerman OW, Stienstra Y, 2016. Case report: multidrug-resistant tuberculosis complicated by nosocomial infection with multidrug-resistant enterobacteriaceae. Am J Trop Med Hyg 94: 517–518.
-
13.
NethMap, 2014. Consumption of Antimicrobial Agents and Antimicrobial Resistance Among Medically Important Bacteria in The Netherlands in 2013. Available at: https://www.wur.nl/upload_mm/1/a/1/0704c512-5b42-4cef-8c1b-60e9e3fb2a62_NethMap-MARAN2014.pdf. Accessed May 22, 2017.
-
14.
Glasner C et al. 2013. Carbapenemase-producing enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 18: pii: 20525.
-
15.
Report S, 2015. Surveillance Report: Antimicrobial Resistance Surveillance in Europe 2014. Available at: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf. Accessed June 8, 2017.
-
16.
Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, Tsalidou M, Maniatis AN, Tsakris A, Sofianou D, 2009. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 64: 348–352.
-
17.
Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS, 2009. Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob Agents Chemother 53: 4048–4050.
-
18.
Voulgari E, Zarkotou O, Ranellou K, Karageorgopoulos DE, Vrioni G, Mamali V, Themeli-Digalaki K, Tsakris A, 2013. Outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in Greece involving an ST11 clone. J Antimicrob Chemother 68: 84–88.
-
19.
Tsakris A, Poulou A, Markou F, Pitiriga V, Piperaki ET, Kristo I, Pournaras S, 2011. Dissemination of clinical isolates of Klebsiella oxytoca harboring CMY-31, VIM-1, and a new OXY-2-type variant in the community. Antimicrob Agents Chemother 55: 3164–3168.
-
20.
Koutsogiannou M, Drougka E, Liakopoulos A, Jelastopulu E, Petinaki E, Anastassiou ED, Spiliopoulou I, Christofidou M, 2013. Spread of multidrug-resistant Pseudomonas aeruginosa clones in a university hospital. J Clin Microbiol 51: 665–668.
-
21.
Tsakris A, Poulou A, Kristo I, Pittaras T, Spanakis N, Pournaras S, Markou F, 2009. Large dissemination of VIM-2-metallo-β-lactamase-producing Pseudomonas aeruginosa strains causing health care-associated community-onset infections. J Clin Microbiol 47: 3524–3529.
-
22.
Tsioutis C, Karageorgos S, Stratakou S, Bolikas E, Astrinaki E, Messaritaki A, Adami M, Georgiladakis A, Kassimati A, Gikas A, 2015. Four years of experience with carbapenem-resistant Gram-negative bacteria in two tertiary care hospitals in Crete, Greece. Antimicrob Resist Infect Control 4 (Suppl 1): P130.
.png)
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug–Resistant Tuberculosis
A Syrian asylum seeker with multidrug–resistant tuberculosis (TB) developed a bronchopleural fistula after pneumonectomy. Although screening tests were negative on admission, carbapenemase-producing Enterobacteriaceae were cultured after a few months of TB treatment. Prevalence of multidrug–resistant organisms is reported to be increased in asylum seekers compared with the general Dutch population. Arduous conditions during transit and interrupted health care delivery in our patient led to multiple-resistant microorganisms that complicated treatment.
Author Notes
Authors’ addresses: Sofanne J. Ravensbergen, Department of Internal Medicine/Infectious Diseases, University Center of Groningen, Groningen, The Netherlands, E-mail: s.j.ravensbergen@umcg.nl. Christina Louka, Department of Medical Microbiology, Tzaneio General Hospital of Piraeus, Athens, Greece, E-mail: cslouka@gmail.com. Mariëtte Lokate and Erik Bathoorn, Department of Medical Microbiology, University Medical Center Groningen, Groningen, The Netherlands, E-mails: m.lokate@umcg.nl and d.bathoorn@umcg.nl. Spyros Pournaras, Department of Microbiology, Faculty of Medicine, National and Kapodistrian University of Athens, Athens, Greece, E-mail: spyrpournaras@yahoo.gr. Tjip S. van der Werf and Ymkje Stienstra, Department of Internal Medicine/Infectious Diseases, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands, E-mails: t.s.van.der.werf@umcg.nl and y.stienstra@umcg.nl. Wiel C. M. de Lange and Onno W. Akkerman, Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, The Netherlands, E-mails: w.c.m.de.lange@umcg.nl and o.w.akkerman@umcg.nl.